Development of phytomolecule based optimized antimicrobial leads applying semi synthetic in vitro and in silico approaches
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Development of phytomolecule based optimized antimicrobial leads applying semi-synthetic, in vitro and in silico approaches
newline
newlineKrishna Narayan Mishra
newline
newlineABSTRACT
newline
newline
newlineThe natural products, particularly plant secondary metabolites, have been the greatest source of modern drugs . Drug discovery from natural resources is a time- and money-consuming and often risky process that may take between 10 and 15 years and costs between $1 and $2 billion for a single drug. Despite the challenges and potential dangers, natural compounds continue to serve as an inexhaustible reservoir of contemporary medications due to their perceived alignment with nature and consequent reputation for safety. Besides time and cost, antimicrobial resistance (AMR) is a global challenge to modern drugs. Several highly efficient antibiotics of the time have now become inactive due to the ever-increasing rise in drug-resistant strains of pathogenic microbes. It has been noted that pharmaceuticals that only target a single enzyme frequently cause resistance and are closely linked to a number of adverse effects as compared to those that work on numerous targets at a time. This can be accomplished efficiently by developing hybrid compounds derived from the combination of bioactive moieties to generate leads with a significantly enhanced and wide range of pharmacological properties. The process of drug discovery and development has been transformed in recent years thanks to Computer-aided drug design (CADD), leading to a reduction in both time and cost of the drug development process as well as fewer drug failures. Within the drug design industry, CADD techniques have had a notable influence by allowing for the rational design and improvement of new antibiotics with enhanced potency and selectivity.
newlineThe work embodied in this thesis represents a cumulative approach to discover and develop novel leads to treat microbial infections, which may further develop into an efficient and cost-effective drug in the future.